-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62

Benzinga·11/06/2026 11:46:33
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $55 to $62.